Tumor-derived sEVs are capable of effectively transporting CRISPR/Cas9 plasmids to tumor tissues, suppressing the expression of poly (ADP-ribose) polymerase-1 (PARP-1). The gene discussed is PARP1; the disease is neoplasm.